Idecabtagene vicleucel

{
  "id": "MLC-T-ONC-004122",
  "term": "Idecabtagene vicleucel",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A treatment used for adults with multiple myeloma that came back or did not get better after treatment with at least two lines of anticancer therapy that included an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Idecabtagene vicleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Idecabtagene vicleucel binds to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body’s immune system kill cancer cells. Idecabtagene vicleucel is a type of cellular immunotherapy called CAR T-cell therapy. Also called Abecma.",
    "A preparation of autologous peripheral blood T lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells."
  ],
  "synonyms": [
    "Abecma",
    "ide-cel",
    "BCMA-specific CAR-expressing T lymphocytes BB2121",
    "Anti-BCMA CAR T Cells BB2121",
    "anti-BCMA-CAR-transduced T cells BB2121"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/idecabtagene-vicleucel/"
}